Purpose of review HOXA9 is a homeodomain transcription factor that plays an essential role in normal hematopoiesis and acute leukemia, in which its overexpression is strongly correlated with poor prognosis. The present review highlights recent advances in the understanding of genetic alterations leading to deregulation of HOXA9 and the downstream mechanisms of HOXA9-mediated transformation.
INTRODUCTION
Homeobox proteins are a family of homeodomaincontaining transcription factors, first identified in Drosophila, that control cell fate and segmental identity during development [1, 2] . In mammals, the 39 class 1 homeobox, or HOX genes, are arranged into four parologous clusters (A, B, C, and D) on separate chromosomes [3, 4] . In addition to their role in regulating development, a subset of A and B cluster HOX genes also play crucial roles in regulating hematopoiesis and leukemogenesis [5] [6] [7] . Of these, HOXA9 has been most intensively studied as it is overexpressed in more than 50% of acute myeloid leukemias (AMLs) and in a subset of B and T acute lymphoblastic leukemias [8, 9, 10 & ]. Understanding the HOXA9 axis -how its expression is regulated in normal and neoplastic states, how it regulates transcription and which downstream targets are essential for transformationmay lead to new therapies in leukemia and other hematologic malignances.
DEREGULATION OF HOXA9 IN ACUTE LEUKEMIA
HOXA9 is expressed in high levels in hematopoietic stem cells (HSCs) and early progenitors, and its expression is downregulated with further differentiation ( Fig. 1a) [11] . Hoxa9-deficient mice show mild pancytopenia and decreased spleen and thymus cellularity [12] . Conversely, overexpression of Hoxa9 in mice leads to HSC expansion and a myeloproliferative disorder that progresses to AML [5] . The onset of these leukemias is rapidly accelerated by coexpression of HOX cofactors, MEIS1 and PBX3, which are often expressed at high levels with HOXA9 in human leukemias [13] [14] [15] [16] .
A variety of upstream genetic alterations can lead to deregulation of HOXA9, including the mixed lineage leukemia gene MLL1 translocations, NUP98fusions, NPM1 mutations, CDX deregulation, MOZfusions, and translocations involving HOXA9 itself [17] . Regardless of the mechanism of deregulation, high-level HOXA9 expression appears to be a strong independent adverse prognostic factor in acute leukemia [8, 9, 18] .
MLL1-fusion proteins
Chromosomal translocations involving MLL1 at chromosome 11q23 occur in about 10% of AML [19, 20] . MLL1 (also known as KMT2A) is a large protein of nearly 4000 amino acids and is one of five mammalian MLL proteins that are homologous to the Drosophila protein Trithorax, a positive regulator of homeobox gene expression in the fly. All MLL proteins share a C-terminal SET domain that has methyltransferase activity specific for histone H3 lysine 4. MLL family members antagonize the action of Polycomb group proteins, which form multisubunit complexes that have histone H3 lysine 27 methyltransferase
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Further study of HOXA9-mediated leukemogenesis is warranted given its central role in development and oncogenesis. activity. MLL1 has been shown to be required for normal hematopoiesis at least in part because of its ability to regulate HOX gene expression ( Fig. 1b ) [21] . Increasing evidence suggests this involves not only histone methylation, but also recruitment of the histone acetyltransferase MOF [22] . Leukemia-associated MLL1 translocations result in fusion of MLL1 to one of more than 60 different translocation partners and deletion of the coding regions for the central PHD domains and C-terminal SET domain. Nine translocation partners (AF1p, AF4, AF6, AF7, AF10, AF17, ENL, ELL, and SEPT7) comprise 90% of MLL translocations [23] . These include both nuclear factors (such as AF4, AF9, and ENL) and less common cytoplasmic partners, such as AF1p and SEPT7 [24] . MLL-fusion proteins enforce high-level HOXA9 expression, which is required for transformation in most experimental models [25, 26] . This mechanism involves recruitment of at least two complexes important for transcriptional regulation. One, the super elongation complex (SEC), contains common MLL-translocation partners ELL, ENL or AF9, AF4, and positive transcription elongation factor b (P-TEFb), which includes the cyclin-dependent kinases CDK9 and Cyclin-T [27] . The other complex includes the histone methyltransferase DOT1L, which specifically methylates histone H3 lysine 79, and the MLL-translocation partners AF10, AF17, AF9, and ENL. MLL-fusion proteins either directly or indirectly recruit the P-TEFb and DOT1L complexes to the HOXA locus, resulting in large increases in histone H3 lysine 79 methylation and high-level transcription ( Fig. 1c ) [28] . DOT1L inhibitors have been shown to have efficacy for MLL-rearranged leukemias and are currently being tested in clinical trials [29,30 & ]. Partial tandem duplications involving the sequence encoding the N-terminus of MLL are observed in about 10% of cytogenetically normal AML and are also associated with HOXA9 overexpression [31] . Interestingly, these have been shown to be sensitive to DOT1L inhibition, despite the fact that they do not involve fusion with partners that interact with DOT1L [32] .
Another attractive therapeutic target for MLLrearranged leukemias is menin, which interacts with the amino terminus of both MLL and MLL-fusion proteins and is required for their recruitment to specific chromosomal sites ( Fig. 1b ). Small molecule inhibitors of the MLL-menin interaction, which are under active development, show considerable efficacy in killing AML cells in vitro and in animal models [33 & ].
Nucleoporin-fusion proteins
Nucleoporins are members of the nuclear pore complex, which facilitates shuttling of metabolites and molecules between the cytoplasm and nucleus and also plays a role in promoting euchromatic transcription [34, 35] . NUP98 and less commonly NUP214 are involved in a number of chromosomal translocations in acute leukemia (reviewed in more detail in [36] ). NUP98 translocations include fusions with clustered HOX genes (A9, A11, A13, C11, C13, D11, and D13), nonclustered HOX genes (HHEX, PRRX1, PRRX2), and non-HOX genes such as NSD1 and JARID1A [37] . These fusions result in HOX gene upregulation, which contributes to leukemogenesis [38] . AML and AMKL cases harboring NUP98 translocations show consistent HOXA and HOXB cluster upregulation, with an overall gene expression signature that is distinct from MLLrearranged leukemias [39, 40] .
NPM1 mutation
Mutations of the chaperone protein nucleophos-min1 (NPM1) are common, occurring in about 50-60% of AMLs [41, 42] . Leukemia-associated NPM1 mutations create an additional nuclear export signal resulting in relocalization of NPM1 from the nucleus to the cytoplasm [43] . Cytoplasmic NPM1 (NPM1c) upregulates the expression of HOXA9, HOXA10, and MEIS1, possibility as a result of cytoplasmic sequestration of HEXIM1 by NPM1c, which subsequently activates P-TEFb [44] [45] [46] .
Other mechanisms of HOXA9 deregulation
Many additional upstream genetic alterations lead to HOXA9 deregulation in acute leukemia [17] . Deletions or decreased expression of the polycomb protein EZH2 leads to leukemia with upregulation of HOXA9 [47] . Similarly, mutations in the polycomb gene ASLX1 are common in myelodysplastic syndromes and are associated with high expression of HOXA9 [48] . In addition, fusion of CDX2 and ETV6 (ETV6-CDX2) is seen in rare cases of AML, resulting in high-level CDX2 expression, which promotes HOXA9 expression [49, 50] . Chromosomal translocations generating the CALM-AF10 (PICALM-MLLT10) fusion leads to HOXA cluster upregulation in T-ALL and some AML cases [38, 51] . The MYST-CREBBP (MOZ-CBP) is seen in de novo and therapyrelated AML cases and is also associated with HOXA9 and MEIS1 upregulation [52] . Finally, rare cases of T-ALL harbor translocations involving the HOXA9 locus with the T-cell receptor b locus, which results in high-level HOXA9 expression [53] .
TRANSCRIPTIONAL REGULATION AND TRANSFORMATION BY H/M
The mechanisms through which HOXA9 regulates downstream gene expression and specific targets that are essential to HOXA9-mediated transformation are areas of active investigation. It is clear that HOXA9 is a member of both activating and repressive transcriptional regulatory complexes, which include cofactor and collaborator proteins that provide target specificity and stabilization on the DNA, and epigenetic modifiers and transcriptional machinery (Fig. 2) [54] [55] [56] . Early studies with small molecules disrupting protein interactions in HOXA9 complexes have been successful at killing leukemia cells both in-vitro and in murine studies [16, [57] [58] [59] . In addition, critical downstream targets of HOXA9 in leukemia are being rapidly identified, providing another avenue for targeted therapies in AML. Two comprehensive review articles were recently published discussing HOX protein function [60, 61] . In the following section, we will highlight the latest publications related to HOXA9 and its cofactors in leukemia.
Cofactors
HOX proteins regulate downstream gene expression through direct binding at cis-regulatory elements via their highly conserved homeodomains. These 60-amino acid domains are responsible for binding to DNA and for providing an interface mediating protein-protein interactions [62, 63] . Although homeodomains are highly conserved across the 39 mammalian HOX proteins, multiple studies suggest that homeodomains confer unique properties via their small differences [64, 65] . For example, swapping the homeodomains of HOXA9 and HOXA1 abolishes the leukemogenic properties of HOXA9 while conferring those properties to HOXA1 [66] .
HOXA9 binds DNA along with a small subset of cofactors, many of which are members of the threeamino-acid-loop-extension (TALE) family. The best characterized of these cofactors is MEIS1, which plays a synergistic causative role in leukemia with HOXA9 [14, 15] . A recent study with a Meis1 knockout/MLL-AF9 knockin murine model established that Meis1 is required for development of MLL-AF9 driven leukemias [67 & ]. This requirement is partially mediated through promoting a low oxidative environment established by direct regulation of HLF by Meis1. In addition, MEIS1 is responsible for recruiting CREB and CBP to HOXA9 binding sites in a GSK-3-dependent manner, which is required for maintaining the MLL stem cell transcriptional program [58] . This interaction can be targeted using GSK-3 inhibitors, leading to growth inhibition of cells transformed by either HOXA9/MEIS1 or MLLfusion proteins [57] [58] [59] . The oncogenic properties of MEIS1 are antagonistically regulated by PREP1, another TALE family protein, through direct competition for binding sites [68] . PREP1 also competitively heterodimerizes and sequesters PBX proteins, thereby decreasing stability of MEIS1 and preventing the MEIS1-DDX3x/DDX5 interactions that are required for tumorigenesis [69, 70] . Furthermore, in-vivo leukemogenesis studies with HOXA9/MEIS1 in PREP1-deficient cells showed more aggressive leukemias compared to wild type [69] . Recent work has characterized the requirement of a second TALE cofactor, PBX3, in the setting of leukemia with high expression of HOXA9. PBX3, and not PBX1 or PBX2, was found to be essential for MLL-fusion protein-mediated transformation. Disruption of the PBX3/HOXA9 interaction with the small molecule HXR9 selectively kills leukemic cells, providing a promising strategy for developing future therapies [16] . PBX3 also dimerizes with MEIS1 and inhibits its ubiquitination and degradation, thereby increasing the half-life of MEIS1 and enhancing the proliferation and colony forming ability of primary cells transduced by HOXA9 [71] . This MEIS1/PBX3 dimerization is required for expression of HOXA9/MEIS1 target genes such as FLT3 and TRIB2 [71] . Moreover, coexpression of MEIS1/PBX3 is sufficient to transform cells in culture and lead to formation of leukemia in vivo with similar latency to that of MLL-AF9 [72] . Expression patterns in cells transformed by MEIS1/PBX3 are consistent with that of the MLL-AF9 core transcriptome, including upregulation of HOXA9 [72] .
Collaborators
It is likely that tissue-specific collaborator proteins provide a final level of binding specificity to HOX complexes [73] . Recent work has shown that collaborators establish areas of chromatin accessibility, provide stability in DNA binding, and help modulate the downstream activity of HOX complexes [74] . Two such collaborators are the lineage-specific transcription factors, PU.1 and C/ EBPa, which are known to establish areas of relaxed chromatin and allow for signal-dependant recruitment of additional proteins [75] . PU.1 was recently found to be essential for MLL-induced leukemias and was shown to directly regulate key genes in the HOX/MEIS signature, including FLT3 and c-KIT [76] . Taken together with previously published work, which found that HOXA9 and PU.1 physically interact and that the PU.1 binding motif is enriched at HOXA9 binding sites, these findings suggest PU.1 may be an essential member of a HOXA9 transcriptional regulatory complex [54] . PU.1 also plays a role in leukemias without MLL translocations, potentially through direct activation of MEIS1 via binding at the MEIS1 promoter [77] .
Multiple recent publications have established that C/EBPa is required for MLL-fusion protein and HOXA9-driven leukemias. Initial studies found that the initiation of MLL-ENL transformed leukemias required C/EBPa, whereas it was not required for maintenance of transformation [78] . Loss of C/ EBPa in MLL-ENL transformed cells also resulted in decreased expression of HOXA9/MEIS1, however re-expression of HOXA9/MEIS1 could not rescue transformation in these cells. Work from our group found that loss of C/EBPa significantly improved survival in murine in-vivo leukemogenesis models of HOXA9/MEIS1-driven AML [10 & ]. We also established that C/EBPa and HOXA9 physically interact and colocalize at more than 50% of HOXA9 binding sites, raising the possibility that C/EBPa is an essential member of the HOXA9-transcriptional regulatory complex. More recent work also suggests that C/EBPa-driven myeloid differentiation, rather than C/EBPa itself, is required for initiation of MLLrearranged leukemia [79] . The failed transformation of MLL-AF9 in C/EBPa deleted cells could be rescued with cytokine induction of GMP formation. It is possible that this requirement is due to the need for myeloid specific enhancers for proper downstream HOXA9 function. Similarly, it is likely that collaborators such as PU.1 and C/EBPa are cell typespecific and that HOXA9 would have different collaborators in B-cell and T-cell leukemias.
Targets in leukemia
Considerable progress has been made toward understanding HOXA9-mediated leukemogenesis through the identification of proleukemic targets with cis-regulatory regions bound by HOXA9 and MEIS1 [54] . Many of these targets have been studied individually and found to play important roles in leukemic transformation (comprehensively reviewed in [60] ). Recently, additional critical targets have been identified and mechanistically studied. HOXA9 was shown to regulate IGF1 expression through binding at an upstream putative promoter and DNA hypersensitive region in intron 1 [80] . IGF1-null cells transformed by HOXA9 have reduced leukemogenic potential and increased apoptosis in response to serum starvation. HOXA9 is also involved in a feedback loop along with HOXA10 that directly regulates CDX4 expression during normal hematopoietic differentiation [81] . In the context of leukemia, MLL-ELL cooperates with constitutively activated SHP2 mutants to block the tyrosine phosphorylation of HOXA9/10 that is required for repression of CDX4, thereby contributing to the sustained expression of CDX4 and leukemic transformation [81] .
Multiple studies have implicated a role for HOXA9 in the regulation of INK4A/B expression, critical mediators of HSC self-renewal, apoptosis, and oncogene-induced senescence whose expression leads to a block in cell cycle at the G 1 phase [82] . Hoxa9 represses Ink4a expression to overcome oncogene-induced senescence during transformation by AML1-ETO in Bmi1 À/À cells, and in Hoxa9/Meis1 transformed cells [10 & ,83] . This repression may be the result of direct recruitment of EZH2 by Hoxa9; however, recent work suggests that EZH2 may also regulate p16 in HOXA9-independent fashion in MLL-rearranged leukemias [84, 85] .
Finally, HOXA9 is involved in antagonistic regulation of GFI-1 target microRNAs, mir-21 and mir-196b, whereby direct binding of HOXA9 to cis-regulatory regions increases expression of these microRNAs [86] . Targeting mir-21 and mir-196b with antagomirs results in specific inhibition of colonyforming activity and leukemia-initiating cell activity in HOXA9, NUP98-HOXA9, and MLL-AF9, and also leads to leukemia-free survival in MLL-AF9 murine leukemogenesis studies. Furthermore, samples from patients with MLL-translocated and NPM1 mutant leukemias showed specific growth inhibition in colony-forming assays when treated with the antagomirs, providing a promising therapeutic approach for HOXA9-driven AML [86] .
CONCLUSION
Although significant progress has been made toward our understanding of the genetic alterations leading to deregulation of HOXA9 and the mechanisms of HOXA9-mediated transformation, many answered questions remain. It will be important to identify the cofactors, interactions and downstream activities of HOXA9 that are essential for leukemogenesis. HOXA9 is associated with both activation and repression of transcription, with the latter being particularly poorly understood. In addition, the downstream targets that are essential for leukemogenesis are only beginning to be defined using genome-wide screening. Given the central role of HOXA9 proteins in development and oncogenesis, further work is warranted which may have broad applicability toward the development of more potent and selective therapies.
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